*	OR T3 T4
R1	Has_qualifier Arg1:T5 Arg2:T3	
R2	Has_temporal Arg1:T7 Arg2:T9	
R3	multi Arg1:T7 Arg2:T8	
R4	Has_value Arg1:T10 Arg2:T11	
R5	AND Arg1:T7 Arg2:T10	
R6	AND Arg1:T5 Arg2:T7	
R7	Has_value Arg1:T14 Arg2:T15	
R8	Has_temporal Arg1:T14 Arg2:T16	
R9	Has_qualifier Arg1:T12 Arg2:T13	
R10	AND Arg1:T12 Arg2:T14	
R11	Has_value Arg1:T18 Arg2:T19	
R12	Has_temporal Arg1:T18 Arg2:T20	
R13	AND Arg1:T17 Arg2:T18	
R14	Has_value Arg1:T21 Arg2:T22	
R15	Has_temporal Arg1:T21 Arg2:T23	
R16	AND Arg1:T24 Arg2:T21	
R17	Has_index Arg1:T27 Arg2:T28	
R18	Has_multiplier Arg1:T25 Arg2:T26	
R19	Has_temporal Arg1:T25 Arg2:T27	
R20	Has_temporal Arg1:T29 Arg2:T30	
*	OR T31 T33 T32
R21	AND Arg1:T31 Arg2:T29	
R22	Has_index Arg1:T38 Arg2:T39	
*	OR T37 T36 T35
R23	Has_temporal Arg1:T37 Arg2:T38	
R24	Has_multiplier Arg1:T41 Arg2:T42	
R25	Has_temporal Arg1:T44 Arg2:T45	
*	OR T48 T47
R26	Has_temporal Arg1:T46 Arg2:T48	
R27	AND Arg1:T43 Arg2:T46	
R28	Has_multiplier Arg1:T46 Arg2:T44	
*	OR T43 T50
R29	AND Arg1:T50 Arg2:T51	
R30	AND Arg1:T41 Arg2:T43	
R31	AND Arg1:T57 Arg2:T58	
*	OR T57 T59
R32	AND Arg1:T56 Arg2:T57	
*	OR T65 T66
R33	Has_temporal Arg1:T65 Arg2:T64	
*	OR T61 T63 T62
R34	AND Arg1:T61 Arg2:T65	
R35	Has_temporal Arg1:T61 Arg2:T67	
R36	Has_qualifier Arg1:T71 Arg2:T72	
*	OR T70 T71
*	OR T73 T75 T76 T77
R37	Has_negation Arg1:T79 Arg2:T78	
R38	AND Arg1:T73 Arg2:T79	
R39	AND Arg1:T74 Arg2:T73	
R40	AND Arg1:T70 Arg2:T74	
R41	Has_multiplier Arg1:T83 Arg2:T82	
*	OR T86 T85
R42	Has_qualifier Arg1:T84 Arg2:T86	
R43	Has_index Arg1:T88 Arg2:T89	
R44	Has_temporal Arg1:T84 Arg2:T88	
R45	AND Arg1:T90 Arg2:T91	
R46	Has_temporal Arg1:T90 Arg2:T92	
R47	Has_temporal Arg1:T93 Arg2:T94	
*	OR T96 T98 T97
R48	Subsumes Arg1:T95 Arg2:T96	
T1	Informed_consent 0 145	Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent
T2	Pregnancy_considerations 147 223	Male or non-pregnant, non-lactating female patients at least 18 years of age
T3	Qualifier 238 246	moderate
T4	Qualifier 250 256	severe
T5	Condition 257 284	Ankylosing Spondylitis (AS)
T7	Condition 307 326	radiologic evidence
T8	Procedure 307 317	radiologic
T9	Temporal 290 295	prior
T10	Measurement 342 375	Modified New York criteria for AS
T11	Value 327 337	fulfilling
T12	Condition 384 386	AS
T13	Qualifier 377 383	Active
T14	Measurement 399 464	total Bath Ankylosing Spondylitis Disease Activity index (BASDAI)
T15	Value 465 468	= 4
T16	Temporal 476 487	at baseline
T17	Condition 489 500	Spinal pain
T18	Measurement 516 534	BASDAI question #2
T19	Value 535 541	= 4 cm
T20	Temporal 552 563	at baseline
T21	Measurement 596 621	visual analog scale (VAS)
T22	Value 622 629	= 40 mm
T23	Temporal 641 652	at baseline
T24	Condition 565 580	Total back pain
T25	Drug 683 729	non-steroidal anti-inflammatory drugs (NSAIDs)
T26	Multiplier 737 759	maximum tolerated dose
T27	Temporal 760 810	for at least 4 weeks prior to their Baseline Visit
T28	Reference_point 790 810	their Baseline Visit
T29	Condition 820 839	inadequate response
T30	Temporal 843 864	for less than 4 weeks
T31	Condition 868 893	withdrawn for intolerance
T32	Condition 868 881;895 903	withdrawn for toxicity
T33	Condition 907 924	contraindications
T35	Drug 1011 1021;958 982	inhibitors Cyclooxygenase-1 (COX-1)
T36	Drug 986 1021	Cyclooxygenase-2 (COX-2) inhibitors
T37	Drug 941 947	NSAIDs
T38	Temporal 1022 1070	for at least 2 weeks before their Baseline Visit
T39	Reference_point 1050 1070	their Baseline Visit
T41	Drug 1100 1144	tumor necrosis factor alpha (TNFa) inhibitor
T42	Multiplier 1146 1163	not more than one
T43	Condition 1190 1209	inadequate response
T44	Multiplier 1255 1268	approved dose
T45	Temporal 1269 1308	for at least 3 months prior to baseline
T46	Procedure 1233 1242	treatment
T47	Temporal 1225 1232	current
T48	Temporal 1213 1221	previous
T50	Condition 1321 1331	intolerant
T51	Drug 1358 1373	anti-TNFa agent
T54	Condition 1375 1403	Total ankylosis of the spine
T55	Competing_trial 1405 1540	Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer.
T56	Condition 1553 1569	hypersensitivity
T57	Drug 1584 1595	study drugs
T58	Drug 1603 1613	excipients
T59	Drug 1620 1653	drugs of similar chemical classes
T61	Procedure 1656 1667	Chest x-ray
T62	Procedure 1669 1702	computerized tomography (CT) scan
T63	Procedure 1707 1745	chest magnetic resonance imaging (MRI)
T64	Temporal 1763 1770	ongoing
T65	Condition 1771 1781	infectious
T66	Condition 1785 1802	malignant process
T67	Temporal 1813 1847	within 3 months prior to screening
T70	Drug 1910 1921	secukinumab
T71	Drug 1935 1948	biologic drug
T72	Qualifier 1929 1934	other
T73	Drug 1968 1990	Interleukin-17 (IL-17)
T74	Condition 1958 1967	targeting
T75	Drug 1992 2020	Interleukin-12/23 (IL-12/23)
T76	Drug 2029 2043	IL-17 receptor
T77	Drug 2058 2089	biologic immunomodulating agent
T78	Negation 2091 2097	except
T79	Drug 2114 2118	TNFa
T82	Multiplier 2144 2157	more than one
T83	Drug 2158 2173	anti-TNFa agent
T84	Procedure 2208 2232	corticosteroid injection
T85	Qualifier 2196 2207	intravenous
T86	Qualifier 2179 2192	intramuscular
T88	Temporal 2233 2263	within 2 weeks before baseline
T89	Reference_point 2255 2263	baseline
T90	Procedure 2280 2306	intra-articular injections
T91	Drug 2313 2327	corticosteroid
T92	Temporal 2329 2359	within 4 weeks before baseline
T93	Procedure 2389 2413	cell-depleting therapies
T94	Temporal 2361 2369	Previous
T95	Drug 2431 2461	high potency opioid analgesics
T96	Drug 2469 2478	methadone
T97	Drug 2480 2493	hydromorphone
T98	Drug 2495 2503	morphine
